CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Quantity Limit Exception Criteria

Defines clinical and documentation criteria for approving exceptions to drug quantity limits for Neighborhood Health Plan of Rhode Island members (Medicaid and Commercial). Applies to provider requests for higher-than-standard dispense quantities or dosing frequencies.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyQuantity Limit Exception Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective Dateas written

Next Review DateN/A

Key ActionProvide documentation of FDA‑approved or compendia‑supported indication, dose/quantity within labeling or compendia, and supporting details for one required justification.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsmaximum coverage duration

7approval condition count

6 datesreview history

Quantity Limit Exception — Coverage Criteria

This policy defines the clinical conditions under which an exception to a drug quantity limit may be authorized. Authorization is considered only when the request meets all elements of Section I: the drug is for an FDA‑approved or medically accepted indication, the requested dose and quantity align with FDA labeling or compendia-supported dosing, and at least one specific justification in Section I.C is documented.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Requests will be denied if they do not meet the approval criteria in Section I. Specifically, requests lacking an FDA‑approved or compendia‑supported indication, or requests where the prescribed dose or quantity fall outside FDA labeling or compendia dosing, or requests that fail to provide one of the required justifications listed under Section I.C (e.g., loading dose intent, weight/BSA dosing with weight provided, intolerance rationale, specific drug interaction, start date for continuation, or documentation of failed lower doses) do not satisfy the criteria for an exception.

Provider Requirements and Authorization Process

Prior Authorization

Quantity limit exception prior authorization

Prior authorization is required when requesting a quantity limit exception. Requests will be considered only when ALL approval criteria in Section I are met, including: an FDA‑approved or compendia‑supported indication; prescribed dose and quantity within FDA labeling or compendia dosing; and at least one of the specific clinical conditions in Section I.C (e.g., loading dose, weight‑based dosing with documented weight/BSA, intolerance to higher strength, dose adjustment for drug interaction with documentation, continuation of stable therapy with start date, or documented failure of lower doses).

Affected requests: quantity limit exceptions and requests for higher maintenance dosing
Documentation required as described in "Required documentation" callouts and Section I

Step Therapy

Step therapy note

When requesting higher maintenance dosing, document prior failure of lower doses as required in Section I.C.f. The prior failure must include the specific regimens tried, durations, and clinical response or adverse effects that led to escalation.

Step therapy requirement: provide specifics of failed lower‑dose regimens (drug, dose, duration, outcome)
If escalation is for intolerance or interaction, include supporting rationale and relevant clinical data

Documentation Required

Required documentation

Provide clinical documentation that supports the requested indication and dosing. At minimum include: diagnosis/indication consistent with FDA labeling or accepted compendia; prescribed dose, frequency, and total quantity with reference to labeling or compendia; relevant patient-specific information (weight/BSA if dosing by weight, start date of current dose if continuation, description of intolerance or drug interaction if applicable); and documentation of prior therapies and outcomes when required (e.g., failed lower doses). Incomplete documentation may result in denial.

Include patient weight/BSA when applicable
If request is for continuation, include start date on current dose
List prior therapies and outcomes when step therapy criteria apply

Key Definitions

Medically accepted indication

DefinitionMedically accepted indication = an indication supported by FDA approval or by one of these standard reference compendia: American Hospital Formulary Service Drug Information (AHFS-DI), Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or peer‑reviewed published medical literature demonstrating sufficient evidence.

Evidence sourcesAccepted compendia and literature include: AHFS‑DI; Thomson Micromedex DrugDex; Clinical Pharmacology; Wolters Kluwer Lexi‑Drugs; peer‑reviewed published medical literature.

Use in approval criteriaRequests must be for an FDA‑approved indication or a medically accepted indication from the listed compendia/literature to meet Criterion A for authorization.

Continuation Therapy Criteria

Continuation therapy

Continuation on requested dose

Continuation: Request for continuation of therapy on the requested dose where patient is stable and not experiencing adverse side effects must include the start date of therapy on the requested dose.

Supports approval under criterion I.C.e; provide start date of current dose.

Required failed regimens / prior therapies
Documentation that the patient tried and failed lower doses of the requested medication and now requires a higher dose (provide specifics of failed regimens).

Background and Policy Purpose

This policy governs exceptions to standard quantity limits when clinical circumstances require larger or different quantities than routine dispensing (for example, loading doses, weight/BSA‑based dosing, intolerance to higher strengths, drug interactions, continuation on a stable dose, or escalation after failed lower doses). The policy relies on FDA labeling and specified standard drug compendia as the basis for acceptable indications and dosing.